Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryan J Sullivan

Showing results (121-130 of 327) with videos related to

Pageof 33
Sort By:
International Journal of Surgery (London, England)|May 3, 2023
Toxicities associated with immune checkpoint inhibitors: a systematic studyXiangyi Kong, Li Chen, Zhaohui Su, et al.
British Journal of Cancer|August 23, 2022
Clinical and genomic correlates of imatinib response in melanomas with KIT alterationsSeungyeon Jung, Emma Armstrong, Alexander Z Wei, et al.
Future Oncology (London, England)|March 11, 2022
STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable <i>BRAF</i> V600-mutant melanomaDirk Schadendorf, Reinhard Dummer, Caroline Robert, et al.
Oncoimmunology|November 20, 2013
BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytesZachary A Cooper, Dennie T Frederick, Vikram R Juneja, et al.
Annals of Neurology|February 23, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing SpectrumDivyanshu Dubey, William S David, Kerry L Reynolds, et al.
Seminars in Arthritis and Rheumatism|November 10, 2018
Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: A single center experienceMeghan J Mooradian, Mazen Nasrallah, Justin F Gainor, et al.
Journal for Immunotherapy of Cancer|March 14, 2023
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapiesMichael B Atkins, Paolo A Ascierto, David Feltquate, et al.
Cancer Research Communications|April 29, 2024
A Phase II Study of ERK Inhibition by Ulixertinib (BVD-523) in Metastatic Uveal MelanomaElizabeth I Buchbinder, Justine V Cohen, Giuseppe Tarantino, et al.
The Oncologist|May 7, 2022
Phase II Study of Cabozantinib in Patients With Bone MetastasisEdwin Choy, Gregory M Cote, M Dror Michaelson, et al.
The Oncologist|May 27, 2018
Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to ActionTomas G Neilan, Mace L Rothenberg, Laleh Amiri-Kordestani, et al.
Pageof 33

Showing results (121-130 of 327) with videos related to

Sort By:
Pageof 33
International Journal of Surgery (London, England)|May 3, 2023
Toxicities associated with immune checkpoint inhibitors: a systematic studyXiangyi Kong, Li Chen, Zhaohui Su, et al.
British Journal of Cancer|August 23, 2022
Clinical and genomic correlates of imatinib response in melanomas with KIT alterationsSeungyeon Jung, Emma Armstrong, Alexander Z Wei, et al.
Future Oncology (London, England)|March 11, 2022
STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable <i>BRAF</i> V600-mutant melanomaDirk Schadendorf, Reinhard Dummer, Caroline Robert, et al.
Oncoimmunology|November 20, 2013
BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytesZachary A Cooper, Dennie T Frederick, Vikram R Juneja, et al.
Annals of Neurology|February 23, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing SpectrumDivyanshu Dubey, William S David, Kerry L Reynolds, et al.
Seminars in Arthritis and Rheumatism|November 10, 2018
Musculoskeletal rheumatic complications of immune checkpoint inhibitor therapy: A single center experienceMeghan J Mooradian, Mazen Nasrallah, Justin F Gainor, et al.
Journal for Immunotherapy of Cancer|March 14, 2023
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapiesMichael B Atkins, Paolo A Ascierto, David Feltquate, et al.
Cancer Research Communications|April 29, 2024
A Phase II Study of ERK Inhibition by Ulixertinib (BVD-523) in Metastatic Uveal MelanomaElizabeth I Buchbinder, Justine V Cohen, Giuseppe Tarantino, et al.
The Oncologist|May 7, 2022
Phase II Study of Cabozantinib in Patients With Bone MetastasisEdwin Choy, Gregory M Cote, M Dror Michaelson, et al.
The Oncologist|May 27, 2018
Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to ActionTomas G Neilan, Mace L Rothenberg, Laleh Amiri-Kordestani, et al.
Pageof 33